Wnt antagonist as therapeutic targets in ovarian cancer. (April 2022)

• Record Type: Journal Article
• Authors: Y., Krithicaa Narayanaa; Perumalsamy, Naveen Kumar; Warrier, Sudha; Perumalsamy, Lakshmi R.; Dharmarajan, Arun
• Is Part Of: International journal of biochemistry & cell biology. Volume 145(2022)
• Publication Date: 2022-04
• Subjects: APC Adenomatous polyposis coli -- APCDD1 Adenomatosis polyposis coli down-regulated 1 -- BIRC5 Survivin, Baculoviral inhibitor of apoptosis repeat-containing 5 -- BMP Bone morphogentic protein -- Ca2+ Calcium -- CD Cluster of Differentiation -- CK1 Casein kinase -- CRD Cysteine rich domain -- CSC Cancer stem cells -- CTNNB1 β-catenin -- DKK Dickkopf -- Dsh Disheveled -- EMT Epithelial-mesenchymal transition -- EOC Epithelial ovarian cancer -- FDA Food and Drug Administeration -- FGF Fibroblast growth factor -- Fzd Frizzled -- GSK3β Glycogen synthase kinase 3β -- IGFBP-4 Insulin-like growth factor binding protein 4 -- JNK c-Jun kinase enzyme -- LRP 5/6 Low-density lipoprotein receptor related protein -- MET Mesenchymal-epithelial transition -- miRNA micro Ribonucleic acid -- MMP Matrix metalloproteinses -- mRNA messenger RNA -- NLD Netrin like domain -- OC Ovarian cancer -- PCOS Polycystic ovarian syndrome -- PDX Patient-derived xenograft -- PCP Planar cell polarity -- PKC Protein kinase C -- ROS Reactive oxygen species -- SFRP Secreted frizzled related protein -- siRNA small interfering RNA -- TCF/LEF T – cell factor/ lymphoid enhancer factor -- UTR Untranslated region -- VEGF Vascular endothelial growth factor -- Waif1 Wnt-activated inhibitory factor 1 -- WIF Wnt Inhibitory factor -- Wnt Wingless-related integration site; Ovarian cancer -- Wnt signaling -- Wnt antagonists -- Cancer stem cell -- Biomarker -- Novel targets; Biochemistry -- Periodicals; Cytology -- Periodicals; Biochemistry -- Periodicals; Cell Biology -- Periodicals; Biochimie -- Périodiques; Cytologie -- Périodiques; Biochimie; Cytologie; Biochemistry; Cytology; Ressource Internet (Descripteur de forme); Périodique électronique (Descripteur de forme); Periodicals; 572.05
• DOI: 10.1016/j.biocel.2022.106191
• Languages: English
• ISSNs: 1357-2725

Abstract

Abstract: Ovarian cancer is a fatal malignancy in women with a low survival rate that demands new therapeutic paradigms. Cancer cells acquire various exclusive alterations to proliferate, invade, metastasize, and escape cell death, acting independently of growth-inducing or growth-inhibiting signals. The nature of cellular signaling in tumorigenesis is interwoven. Wnt signaling is an evolutionarily conserved signaling cascade that has been shown to regulate ovarian cancer pathogenesis. The molecular mechanism of Wnt signaling underlying the development of ovarian cancer, drug resistance, and relapse is not completely understood. Extracellularly secreted Wnt signaling inhibitors are crucial regulators of ovarian cancer tumorigenesis and malignant properties of cancer stem cells. Wnt inhibitors arbitrated modifications affecting Wnt pathway proteins on the cell membranes, in the cytoplasm, and in the nucleus have been shown to span essential contributions in the initiation, progression, and chemoresistance of ovarian cancer. Although many extrinsic inhibitors developed targeting the downstream components of the Wnt signaling pathway, investigating the molecular mechanisms of endogenous secreted inhibitors might substantiate prognostic or therapeutic biomarkers development. Given the importance of Wnt signaling in ovarian cancer, more systematic studies combined with clinical studies are requisite to probe the precise mechanistic interactions of Wnt antagonists in ovarian cancer. This review outlines the latest progress on the Wnt antagonists and ovarian cancer-specific regulators such as micro-RNAs, small molecules, and drugs regulating these Wnt antagonists in ovarian tumourigenesis.